(PharmaNewsWire.Com, August 02, 2019 ) Immunofluorescence assay is a powerful technique used to analyze the distribution of glycans, proteins, and small biological and non-biological molecules (cells and tissues) using antibodies conjugated with a fluorescent dye.
The Immunofluorescence Assay market is expected to reach USD 2.01 Billion by 2023 from USD 1.43 Billion in 2017, at a CAGR of 5.8%
The global market is segmented into indirect and direct immunofluorescence. In 2017, the indirect immunofluorescence accounted for the largest share of the market. The advantages of this technique, such as its sensitivity, flexibility, better amplification of the signal, and lower cost over direct immunofluorescence is the key factor increasing the adoption of this technique.
The infectious diseases segment accounted for the largest share of the global immunofluorescence assay market in 2017. The large share of this segment is attributed to the increasing prevalence of infectious diseases across the globe and the widespread adoption of immunofluorescence techniques for the study and diagnosis of infectious diseases.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
